Perl A, Martinelli G, Cortes J, et al. Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3MUT+) relapsed/refractory (R/R) acute myeloid leukemia (AML): results from the phase 3 ADMIRAL trial. 24th Congress of EHA, abstract A876.
MRD-status 1 jaar na stamceltransplantatie geassocieerd met overleving na 6 jaar
jun 2024 | MM, Stamceltransplantatie